These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

308 related articles for article (PubMed ID: 10608623)

  • 1. Evaluation of meningococcal meningitis vaccination strategies for the meningitis belt in Africa.
    Miller MA; Wenger J; Rosenstein N; Perkins B
    Pediatr Infect Dis J; 1999 Dec; 18(12):1051-9. PubMed ID: 10608623
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Emergency vaccination against epidemic meningitis in Ghana: implications for the control of meningococcal disease in West Africa.
    Woods CW; Armstrong G; Sackey SO; Tetteh C; Bugri S; Perkins BA; Rosenstein NE
    Lancet; 2000 Jan; 355(9197):30-3. PubMed ID: 10615888
    [TBL] [Abstract][Full Text] [Related]  

  • 3. [Microeconomic evaluation of a mass preventive immunisation campaign against meningococcal meningitis and yellow fever in Senegal in 1997].
    da Silva A; Parent du Châtelet I; Beckr Gaye A; Dompnier JP; Seck I
    Sante; 2003; 13(4):215-23. PubMed ID: 15047438
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Serogroup A meningococcal conjugate (PsA-TT) vaccine coverage and measles vaccine coverage in Burkina Faso--implications for introduction of PsA-TT into the Expanded Programme on Immunization.
    Meyer SA; Kambou JL; Cohn A; Goodson JL; Flannery B; Medah I; Messonnier N; Novak R; Diomande F; Djingarey MH; Clark TA; Yameogo I; Fall A; Wannemuehler K
    Vaccine; 2015 Mar; 33(12):1492-8. PubMed ID: 25636915
    [TBL] [Abstract][Full Text] [Related]  

  • 5. [An epidemic of meningococcal meningitis in the region of Savanes in Togo in 1997: research and control strategies].
    Aplogan A; Batchassi E; Yakoua Y; Croisier A; Aleki A; Schlumberger M; Molina S; Sidatt M; Kaninda AV
    Sante; 1997; 7(6):384-90. PubMed ID: 9503496
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Serogroup A meningococcal conjugate vaccine coverage after the first national mass immunization campaign-Burkina Faso, 2011.
    Centers for Disease Control and Prevention (CDC)
    MMWR Morb Mortal Wkly Rep; 2012 Dec; 61(50):1022-4. PubMed ID: 23254256
    [TBL] [Abstract][Full Text] [Related]  

  • 7. The cost-effectiveness of alternative vaccination strategies for polyvalent meningococcal vaccines in Burkina Faso: A transmission dynamic modeling study.
    Yaesoubi R; Trotter C; Colijn C; Yaesoubi M; Colombini A; Resch S; Kristiansen PA; LaForce FM; Cohen T
    PLoS Med; 2018 Jan; 15(1):e1002495. PubMed ID: 29364884
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Economics of an adolescent meningococcal conjugate vaccination catch-up campaign in the United States.
    Ortega-Sanchez IR; Meltzer MI; Shepard C; Zell E; Messonnier ML; Bilukha O; Zhang X; Stephens DS; Messonnier NE;
    Clin Infect Dis; 2008 Jan; 46(1):1-13. PubMed ID: 18171206
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Serogroup A meningococcal conjugate vaccination in Burkina Faso: analysis of national surveillance data.
    Novak RT; Kambou JL; Diomandé FV; Tarbangdo TF; Ouédraogo-Traoré R; Sangaré L; Lingani C; Martin SW; Hatcher C; Mayer LW; Laforce FM; Avokey F; Djingarey MH; Messonnier NE; Tiendrébéogo SR; Clark TA
    Lancet Infect Dis; 2012 Oct; 12(10):757-64. PubMed ID: 22818241
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Cost-effectiveness of expanding childhood routine immunization against Neisseria meningitidis serogroups C, W and Y with a quadrivalent conjugate vaccine in the African meningitis belt.
    Kuznik A; Iliyasu G; Lamorde M; Mahmud M; Musa BM; Nashabaru I; Obaro S; Mohammed I; Habib AG
    PLoS One; 2017; 12(11):e0188595. PubMed ID: 29190699
    [TBL] [Abstract][Full Text] [Related]  

  • 11. The burden of meningococcal meningitis in the African Meningitis Belt, from 2009 to 2014: a trend analysis.
    Jaca A; Wiyeh AB; Sambala EZ; Wiysonge CS
    Pan Afr Med J; 2021; 39():57. PubMed ID: 34422180
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Status of the Rollout of the Meningococcal Serogroup A Conjugate Vaccine in African Meningitis Belt Countries in 2018.
    Bwaka A; Bita A; Lingani C; Fernandez K; Durupt A; Mwenda JM; Mihigo R; Djingarey MH; Ronveaux O; Preziosi MP
    J Infect Dis; 2019 Oct; 220(220 Suppl 4):S140-S147. PubMed ID: 31671448
    [TBL] [Abstract][Full Text] [Related]  

  • 13. [Which vaccination strategies for African meningococcal meningitis?].
    Saliou P; Debois H
    Bull Soc Pathol Exot; 2002 Dec; 95(5):326-30. PubMed ID: 12696369
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Evaluation of meningitis surveillance before introduction of serogroup a meningococcal conjugate vaccine - Burkina Faso and Mali.
    Centers for Disease Control and Prevention (CDC)
    MMWR Morb Mortal Wkly Rep; 2012 Dec; 61(50):1025-8. PubMed ID: 23254257
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Bacterial meningitis epidemiology and return of Neisseria meningitidis serogroup A cases in Burkina Faso in the five years following MenAfriVac mass vaccination campaign.
    Diallo AO; Soeters HM; Yameogo I; Sawadogo G; Aké F; Lingani C; Wang X; Bita A; Fall A; Sangaré L; Ouédraogo-Traoré R; Medah I; Bicaba B; Novak RT;
    PLoS One; 2017; 12(11):e0187466. PubMed ID: 29095907
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Eliminating epidemic Group A meningococcal meningitis in Africa through a new vaccine.
    LaForce FM; Okwo-Bele JM
    Health Aff (Millwood); 2011 Jun; 30(6):1049-57. PubMed ID: 21653956
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Effectively introducing a new meningococcal A conjugate vaccine in Africa: the Burkina Faso experience.
    Djingarey MH; Barry R; Bonkoungou M; Tiendrebeogo S; Sebgo R; Kandolo D; Lingani C; Preziosi MP; Zuber PL; Perea W; Hugonnet S; Dellepiane de Rey Tolve N; Tevi-Benissan C; Clark TA; Mayer LW; Novak R; Messonier NE; Berlier M; Toboe D; Nshimirimana D; Mihigo R; Aguado T; Diomandé F; Kristiansen PA; Caugant DA; Laforce FM
    Vaccine; 2012 May; 30 Suppl 2():B40-5. PubMed ID: 22607898
    [TBL] [Abstract][Full Text] [Related]  

  • 18. [Study of the immunization coverage determinants of vaccination campaign against meningococcal A meningitis in Burkina Faso].
    Ouatara S; Faye A; Leye MM; Niang K; Tal-Dia A
    Rev Epidemiol Sante Publique; 2015 Dec; 63(6):347-53. PubMed ID: 26547670
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Costs of Neisseria meningitidis Group A Disease and Economic Impact of Vaccination in Burkina Faso.
    Colombini A; Trotter C; Madrid Y; Karachaliou A; Preziosi MP
    Clin Infect Dis; 2015 Nov; 61 Suppl 5(Suppl 5):S473-82. PubMed ID: 26553677
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Meningococcal meningitis: vaccination outbreak response and epidemiological changes in the African meningitis belt.
    Carod Artal FJ
    Int Health; 2015 Jul; 7(4):226-7. PubMed ID: 25878213
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 16.